Kyntra Bio (KYNB) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Kyntra Bio (KYNB) is Moderate Underperform.

The composite score behind that read is -0.24, weighing +0.00 of bullish evidence against -0.44 bearish.

Kyntra Bio last closed at $5.96, -2.77% on the session.

Against the IVW growth benchmark the position is -1.54% over the forecast window.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

19 graded predictions for KYNB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Kyntra Bio in the 96th percentile on return on equity, where 100 is best.

Kyntra Bio is classified under Health Care / Biotechnology, with a market capitalisation of $24.82M.

StockMap tracks Kyntra Bio as the 331st largest of the 380 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 304 Neutral, 65 Moderate Underperform and 11 Moderate Outperform.

On that composite Kyntra Bio ranks 345th of 380 in the group, against a group median of -0.10.